Skip to main content

Table 2 Resistance pattern of ESBL, MBL and AmpC producing isolates

From: Community acquired multi-drug resistant clinical isolates of Escherichia coli in a tertiary care center of Nepal

Antibiotics

ESBL (n = 48)

MBL (n = 30)

Amp C (n = 18)

 

No. of resistant isolates (%)

No. of resistant isolates (%)

No. of resistant isolates (%)

Ampicillin

44 (91.7)

24 (80.0)

18 (100)

Ampicillin-sulbactam

44 (91.7)

24 (80.0)

18 (100)

Cefazolin

48 (100)

28 (93.3)

16 (88.9)

Ceftazidime

48 (100)

30 (100)

18 (100)

Ceftriaxone

48 (100)

24 (80.0)

12 (66.7)

Cefepime

36 (75.0)

16 (53.3)

0 (0)

Cefoxitin

34 (70.8)

26 (86.7)

18 (100)

Piperacillin-tazobactam

22 (45.8)

18 (60.0)

12 (66.7)

Ticarcillin-clavulanic acid

44 (91.7)

22 (73.3)

16 (88.9)

Amoxicillin-clavulanic acid

48 (100)

30 (80.0)

18 (100)

Aztreonam

48 (100)

22 (73.3)

12 (66.7)

Imipenem

2 (4.2)

14 (46.7)

4 (22.2)

Meropenem

32 (66.7)

22 (73.3)

12 (66.7)

Gentamicin

14 (29.2)

18 (60.0)

6 (33.3)

Amikacin

2 (4.2)

16 (53.3)

4 (22.2)

Tobramicin

16 (33.3)

16 (53.3)

6 (33.3)

Ciprofloxacin

46 (95.8)

28 (93.3)

18 (100)

Ofloxacin

40 (83.3)

24 (80.0)

14 (77.8)

Cotrimoxazole

40 (83.3)

24 (80.0)

12 (66.7)

Chloramphenicol

6 (12.5)

14 (46.7)

4 (22.2)

Colistin

0 (0)

0 (0)

0 (0)